Mai Capital Management Viracta Therapeutics, Inc. Transaction History

Mai Capital Management

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$0.5 - $1.17 $168,340 - $393,915	-336,680 Reduced 92.47%	27,417 $14,000
Q1 2024 May 08, 2024	BUY	$0.48 - $1.13 $4,145 - $9,759	8,637 Added 2.43%	364,097 $371,000
Q4 2023 Feb 09, 2024	SELL	$0.44 - $1.04 $18,572 - $43,898	-42,210 Reduced 10.61%	355,460 $202,000
Q3 2023 Nov 14, 2023	BUY	$1.03 - $1.58 $92,803 - $142,358	90,100 Added 29.29%	397,670 $413,000
Q2 2023 Aug 02, 2023	SELL	$0.89 - $2.13 $63,989 - $153,142	-71,898 Reduced 18.95%	307,570 $433,000
Q1 2023 May 10, 2023	SELL	$1.38 - $2.29 $65,478 - $108,655	-47,448 Reduced 11.11%	379,468 $603,000
Q4 2022 Feb 09, 2023	SELL	$1.26 - $4.38 $265,513 - $922,975	-210,725 Reduced 33.05%	426,916 $623,000
Q3 2022 Nov 15, 2022	SELL	$3.32 - $5.69 $34,225 - $58,658	-10,309 Reduced 1.59%	637,641 $2.72 Million
Q2 2022 Jul 19, 2022	BUY	$1.87 - $5.0 $499,592 - $1.34 Million	267,162 Added 70.16%	647,950 $2.51 Million
Q1 2022 May 10, 2022	BUY	$2.23 - $4.76 $849,157 - $1.81 Million	380,788 New	380,788 $1.81 Million

5.63M

Ticker VIRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,558,200
Market Cap $9.39M
Description
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...

Get notified when there are updates to the investment portfolio of Mai Capital Management, based on Form 13F filings with the SEC.

Stay updated on Mai Capital Management with notifications on news.